Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles

Shaare Zedek Medical Center

Status: Unknown

Conditions: Pregnancy Rate

Treatments: Drug: Decapeptyl 0.1 mg after embryo transfer

Study type: Interventional

Funder types: Other

Identifiers

NCT00542126

GnRHFETsupport.CTIL

Details and patient eligibility

About

Supraphysiological hormonal stimulation enables collecting many oocytes in an In-Vitro Fertilization treatment, but may have a negative effect on uterine function and contribute the fact that the majority of preembryos placed in the uterus fail to implant.

Several medical agents were shown to be beneficial when given in the luteal phase of an IVF cycle, but the optimal regimen has not been yet determined. In 2006, a European group reported that addition of GnRH analog (Decapeptyl) as luteal support in IVF cycle significantly improved pregnancy and delivery rates. It is not known whether this positive effect influences the corpus luteum, embryo or the uterus. The researchers sought to evaluate the effect of GnRH administration as luteal support in frozen-thaws IVF cycle.

Sex: Female

Ages: 18 to 38 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

IVF patients transfer of a minimum of two medium-quality thawed embryos in IVF

Exclusion criteria

1. Two or more fresh IVF embryo transfer or three or more thawed embryos transfer with no pregnancy.
2. maximal endometrial thickness < 6 mm or intracavitary fluid at the time of embryo transfer on previous cycles
3. Untreated hydrosalpinges
4. intracavitary mass
5. submucous myoma
6. known allergy to one of medical agents used in the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

1

Active Comparator group

Description:

GnRH analog administration following embryo transfer

Treatment:

Drug: Decapeptyl 0.1 mg after embryo transfer

2

No Intervention group